Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligns with the provided Cosentyx label excerpts for IL-17A targeting, infection risk, and avoidance of live vaccines; however, several additional claims (e.g., combination with other immunosuppressives, clinician review of medication lists, and framed small-molecule interaction/timing guidance) are not supported by the supplied label text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is an antibody that targets IL-17A.
Supported by 12.1 (selectively binds IL-17A).
Live vaccines are typically not recommended during treatment with immunomodulating therapies like Cosentyx.
Supported by 5.7 and 17 (avoid use of live vaccines; patient counseling).
Cosentyx can increase susceptibility to infections.
Supported by 5.1 and 17 (may increase risk of infections; may lower ability to fight infections).
Before starting or changing Cosentyx, patients typically should mention any history of recurrent or chronic infections or current infections.
Supported by 5.1 and 17 (communicate history of infections; exercise caution with chronic/recurrent infection).
Unsupported Statements
Combining Cosentyx with other immunosuppressing therapies can raise overall infection risk.
Not supported by the provided label sections/excerpts.
Clinicians usually review the full medication list before starting or continuing Cosentyx.
Not supported by the provided label sections/excerpts.
For many small-molecule drugs used for pain, blood pressure, or diabetes, clinically significant direct drug-drug interactions with secukinumab are usually not the main concern.
Not supported by the provided label sections/excerpts.
The main practical issue with concomitant small-molecule drugs is whether a given medicine increases infection risk or requires special timing around vaccinations.
Not supported by the provided label sections/excerpts.
Before starting or changing Cosentyx, patients typically should tell their clinician about all prescription drugs, over-the-counter medicines, and supplements.
Not supported by the provided label sections/excerpts.
Before starting or changing Cosentyx, patients typically should ask specifically about vaccine plans, especially whether any are live.
Label supports avoiding live vaccines/considering immunizations but does not explicitly state that patients should 'ask specifically' in this way.
If a live vaccine was recently given or if immunosuppressive medications are already in use, the prescriber generally weighs timing and infection risk and may adjust the treatment plan.
The label excerpts provided support live vaccine avoidance and infection caution but do not support the specific wording about 'immunosuppressive medications already in use' and the prescriber 'may adjust the treatment plan' phrasing.
Contradictions
Important Omissions
No claims in the evaluated response covered contraindications, boxed warnings, or other safety sections not included in the provided label excerpts (e.g., serious specific boxed/warning elements beyond infections/immunizations).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are label-consistent (infection risk; avoid live vaccines; communicate infection history), but other statements are not supported by the provided label excerpts, including immunosuppressive-combination infection risk and specific interaction/timing framing for small-molecule drugs. Unsupported or overconfident counseling could lead to inaccurate patient/clinician expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts (especially medication-list review, combination with other immunosuppressives, and broad small-molecule interaction framing). Some immunization/vaccine-advice claims use phrasing ('ask specifically', 'immunosuppressive medications already in use', 'may adjust treatment plan') not explicitly stated in the excerpts.
Suggested Improvement
Constrain claims to the supplied label text: IL-17A mechanism (12.1), infection risk and related management (5.1), and avoidance of live vaccines with immunization considerations and patient counseling (5.7, 17). Avoid adding unsupported generalizations about concomitant immunosuppressive therapy and broad small-molecule interaction/timing conclusions unless supported by provided label text.